Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05010577 · ClinicalTrials.gov registry record · Phase 1
Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection
A Phase 1 study, sponsored by BiomX.
- Completed
- Registry status
- Phase 1
- Development phase
- 43
- Enrollment target
NCT05010577 is a Phase 1 study that has completed, run by BiomX. The registered enrollment target is 43 participants.
The verdict
NCT05010577, a Phase 1 study, has completed, sponsored by BiomX.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 43 participants
- Enrollment target
Study Summary
This is a Phase 1b/2a study with the primary objective to determine if BX004-A is safe and tolerable. Exploratory objectives include whether BX004-A reduces sputum Pseudomonas aeruginosa (PsA) bacterial load in CF subjects with chronic PsA pulmonary infection.
Interventions
- DRUG Placebo
- DRUG BX004-A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2022-06-21 |
| Est. Completion | 2024-03-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05010577
The ClinicalTrials.gov registry entry for NCT05010577 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BiomX, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05010577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05010577 about?
NCT05010577 is a clinical study titled "Nebulized Bacteriophage Therapy in Cystic Fibrosis Patients With Chronic Pseudomonas Aeruginosa Pulmonary Infection". This is a Phase 1b/2a study with the primary objective to determine if BX004-A is safe and tolerable. Exploratory objectives include whether BX004-A reduces sputum Pseudomonas aeruginosa (PsA) bacterial load in CF subjects with chronic PsA pulmonary infection.
What is the current status of trial NCT05010577?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 43 participants. The study started on 2022-06-21. Estimated completion is 2024-03-10.
What interventions are being tested in trial NCT05010577?
The interventions under investigation include: Placebo (DRUG), BX004-A (DRUG).
Who is sponsoring clinical trial NCT05010577?
This trial is sponsored by BiomX, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.